Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Multiomics analyses

Checking immunotoxicity risks of checkpoint blockade

Nature Cancer volume 4, pages 779–780 (2023)Cite this article

Subjects

Given the increasing use of immune-checkpoint inhibitors for treating cancer, immune-related adverse events — and markers to prevent and diagnose these — are coming into focus. A systematic analysis investigates genetic, molecular, cellular and clinical risk factors of such adverse events in a large pan-cancer cohort treated with multiple agents.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Multiomic analyses reveal risk factors for irAEs of cancer immunotherapy.

References

  1. Ledford, H. Nature 471, 561 (2011).

    Article  CAS  PubMed  Google Scholar 

  2. Ramos-Casals, M. et al. Nat. Rev. Dis. Primers 6, 38 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  3. Schneider, B. J. et al. J. Clin. Oncol. 39, 4073–4126 (2021).

    Article  CAS  PubMed  Google Scholar 

  4. Haanen, J. et al. Ann. Oncol. 29, iv264–iv266 (2018).

    Article  CAS  PubMed  Google Scholar 

  5. Conroy, M. & Naidoo, J. Nat. Commun. 13, 392 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Glehr, G. et al. Front. Immunol. 13, 1011040 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Sung, C. et al. Nat. Cancer https://doi.org/10.1038/s43018-023-00572-5 (2023).

  8. Mantovani, A., Cassatella, M. A., Costantini, C. & Jaillon, S. Nat. Rev. Immunol. 11, 519–531 (2011).

    Article  CAS  PubMed  Google Scholar 

  9. Chen, H. et al. J. Immunother. Cancer 11, e005527 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  10. Verschueren, E. et al. Cell 182, 329–344.e319 (2020).

    Article  CAS  PubMed  Google Scholar 

  11. Nuñez, N. G. et al. Med. 4, 113–129.e117 (2023).

    Article  PubMed  Google Scholar 

  12. Das, S. & Johnson, D. B. J. Immunother. Cancer 7, 306 (2019).

    Article  PubMed  PubMed Central  Google Scholar 

  13. Amoroso, V. et al. ESMO Open 8, 100787 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Madjar, K. et al. Front. Oncol. 13, https://doi.org/10.3389/fonc.2023.1138305 (2023).

  15. Park, H. J. et al. Yonsei Med. J. 57, 118–126 (2016).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Biocenter, Institute of Bioinformatics, Medical University of Innsbruck, Innsbruck, Austria

    Dietmar Rieder & Zlatko Trajanoski

Authors
  1. Dietmar Rieder
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zlatko Trajanoski
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zlatko Trajanoski.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rieder, D., Trajanoski, Z. Checking immunotoxicity risks of checkpoint blockade. Nat Cancer 4, 779–780 (2023). https://doi.org/10.1038/s43018-023-00561-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43018-023-00561-8

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer